Skip to main content

Table 1 Case Summary

From: Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

Case #

Age at fingolimod cessation (Y)

Sex

Disease Duration (Y)

Prior DMTs

Treatment duration on fingolimod (Y)

ALC/CD4 at the time of stopping fingolimod (cells/uL)

Wash out period (W)

ALC/CD4 baseline to start DMF (cells/uL)

Treatment duration at time of relapse (W)

ALC/CD4 at the time of relapse (cells/uL)

New/Gd+ lesions at the time of relapse

Response to IV steroid treatment (Yes/No)

1

37

F

10

INF-β (Rebif)

5

300/33

8

1400/ND

5

1700/615

Brain & Cervical spine

Yes

2

34

F

13

GA (Copaxone)

4

282/<20

11

644/ND

<1 (4 days)

626/252

Brain & Cervical spine

Yes

3

33

M

3

None

3

567/61

7

1006/389

10

950/ND

Brain & Cervical spine

Yes

4

50

F

4

INF-β (Rebif & Plegridy)

1

270/<20

8

1000/551

14

-

Brain, Cervical & Thoracic spine

Yes

5

42

F

11

None

5.5

467/20

9

1036/295

13

1241/ND

Brain

Yes

6

33

F

8

GA (Copaxone) & INF-β (Plegridy)

1

509/<20

5

912/ND

18

1600/ND

Brain & Thoracic spine

Yes

  1. Absolute lymphocyte count (ALC): Normal reference range 850-3900 cells/ul (Quest Diagnostics)
  2. Absolute CD4+ lymphocyte count: Normal reference range 490-1740 cells/ul (Quest Diagnostics)
  3. ND Not done, Y Year, W Week, Gd + Lesions Gadolinium enhancing lesions